Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Pharmaceuticals
Iceni to repurpose Merck’s cilengitide
by Alex Scott
June 6, 2016
| A version of this story appeared in
Volume 94, Issue 23
Scottish DNA vaccines developer BigDNA has renamed itself Iceni Pharmaceuticals and relaunched to focus on repurposed cancer therapies. The firm’s lead candidate is cilengitide, a cyclic peptide. Cilengitide was initially developed by the Technical University of Munich and Merck KGaA, but it failed late-stage clinical trials for treating glioblastoma, an aggressive brain cancer. Iceni has demonstrated in preclinical trials that cilengitide is effective in a combination therapy for treating myeloma, a bone cancer. Iceni plans to begin Phase II trials in 2017.
You might also like...
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter